TB-500 FAQ connects your treatment questions with what studies found.
Researchers selected a short stretch of a protein to study how cells reach wounds. Later healing tests usually gave the source protein, leaving the copied chain’s effects in you unknown.
TB-500 leaves out most of the protein used in repair studies
TB-500 copies seven linked parts from thymosin beta-4, a protein containing forty-three amino acids [1][5]. Amino acids are the small parts joined together to form proteins.
The shorter chain has been studied and used in work with animals, without an approved treatment use [5]. You can't assume the copied part will give the longer protein's healing effects.
TB-500’s name describes neither TB-500 approval nor a treatment amount
The TB in TB-500 refers to thymosin beta, the source protein's name. The name identifies the copied thymosin beta-4 stretch used in laboratory and animal work [5].
The 500 belongs to the product-style name, rather than describing the chain's chemistry. A name doesn't establish that the substance is approved for your treatment.
TB-500 injury findings mainly concern animals or laboratory cells
Researchers study wounds, hearts, brains, blood vessels, and hair using thymosin beta-4 and its copied stretch [3][4][5]. Most findings involve animals or cells grown for laboratory tests.
Useful healing from the shorter chain remains unproved in people receiving treatment [5]. Your question needs findings about people receiving the substance offered to you.
TB-500’s copied stretch holds a protein that cells need for movement
Actin is a protein whose pieces join into strands that help cells move. TB-500 copies thymosin beta-4's stretch that holds spare actin pieces apart [1][5].
Thymosin beta-4 holds actin 1:1, one of each protein joined together [1][2]. That reserve supports movement, but the copied chain hasn't shown matching human healing benefits for you [5].
TB-500 is a peptide rather than a muscle-building steroid
TB-500 contains linked protein parts in a short chain, the type called a peptide [5]. The copied chain contains seven parts and differs in structure from steroids.
Muscle-building steroids act through hormones, the body's chemical messengers. The proposed repair role instead involves thymosin beta-4 holding actin, a protein used for cell movement [1].
Being a different type of substance doesn't establish a safe treatment. Your safety still needs human findings about TB-500.
TB-500 half-life cannot yet tell you when the chain leaves your blood
Half-life means the time until half a measured amount has left the blood [5]. That time hasn't been established for the TB-500 chain in people.
In the early safety study, Phase 1, researchers found larger thymosin beta-4 amounts cleared more slowly [6]. Horse tests detect prohibited TB-500 use, without telling you the human clearing time [5].
TB-500 side effects cannot be given as your odds of harm
Finished trials haven't measured TB-500 harms against people receiving different care [5]. The Phase 1 early safety test used thymosin beta-4, tolerated up to 1260 milligrams [6].
Questions remain about tumor growth or extra blood reaching tumors with the shorter chain [7]. The TB-500 side effects page explains what that concern means for you.
TB-500 cancer concerns remain possible risks without proof of human harm
High thymosin beta-4 levels in several cancers are linked with the cancer spreading [7][8]. More moving cells and added vessels might, in theory, help cancer grow [7].
Those findings don't establish cancer caused by the shorter chain in people [5]. Your care still faces an unanswered risk, rather than proof of safety.
TB-500 use for years lacks a human finding of safety
Human studies haven't established safety during years of TB-500 use [5]. A comparison study instead gave thymosin beta-4 into a vein for 14 days [6].
A mouse experiment gave shots around the belly organs for 6 months [9]. These studies don't settle your long-term safety, including possible support for tumor growth [7].
TB-500 claims need to account for animal failures and uncertain supplies
Thymosin beta-4 increased mouse muscle fibers without improving strength, heart pumping, or scarring [9]. Thymosin beta-4 treatment in pigs also failed to limit heart damage from stopping and restarting blood flow [14].
Research bottles add a separate problem because their contents may be uncertain [5]. Growth alone doesn't establish useful recovery, and a label alone doesn't establish what was received.
TB-500 safety has not been shown by the study of another protein
Human comparison trials haven't established safety for the TB-500 copied chain [5]. Volunteers instead received thymosin beta-4 through a vein, tolerating up to 1260 milligrams [6].
Possible tumor growth and added blood reaching tumors still need answers [7][8]. Your safety can't be inferred from the absence of tests of the copied part.
TB-500 muscle claims do not establish earlier return of strength
Thymosin beta-4 drew cells that make muscle toward injuries in animal work [5]. A 6-month mouse study found extra fibers, without a useful strength gain [9].
Human trials have yet to prove muscle recovery from the copied part [5]. Your torn muscle needs evidence of useful recovery beyond growth in mice.
TB-500 heart claims involve different injuries in different animals
Thymosin beta-4 improved heart pumping after an artery blockage and kept more heart cells alive in mice [2]. In pigs, treatment didn't reduce heart damage from stopping and restoring blood flow [14].
The animals underwent different tests and received thymosin beta-4. Their results can't establish your heart's response to the copied part.
TB-500 vessel growth could have different meanings for wounds and cancer
Thymosin beta-4 helped vessel-lining cells move and encouraged more blood vessels to form [10]. Added blood can nourish damaged skin or feed a growing tumor.
That shared need raises concern, without proving harm in people receiving treatment [7]. Your safety depends on where growth occurs and whether useful healing follows.
TB-500 stroke treatment has no human benefit shown by the rat amounts
Rats improved after stroke with thymosin beta-4 at 2 and 12 milligrams per kilogram. Treatment at 18 milligrams per kilogram produced no clear benefit in the rats [4].
A kilogram measures weight, so each rat's weight determined the amount received. Your stroke treatment can't be established by another substance's effects in rats.
TB-500 hair claims concern tissue around animal hair roots
Thymosin beta-4 made immature hair-root cells move and develop in rats and mice [5][11]. Hair grew while proteins that clear space in surrounding tissue became more plentiful.
Tissue clearing lets root cells move, helping explain interest in hair growth. You still lack human findings that establish hair regrowth from TB-500 [5].
TB-500 swelling relief remains a question despite eye laboratory findings
Eye tests found thymosin beta-4 reduced activity tied to inflammation, the response that can cause painful swelling [12]. A review described less inflammation near injuries as well [5].
The work involved animals and laboratory cells, rather than people receiving treatment. Human findings haven't established that the copied part eases your swollen tissue.
TB-500 wound evidence belongs to the longer protein given to rats
Thymosin beta-4 led to 42% more covering skin in rats after 4 days. After 7 days, growth was up to 61% greater than with salt-water treatment.
Blood vessels and collagen increased; collagen gives strength to skin as a wound heals. In dishes, skin cells moved more with 10 picograms; each picogram weighs a trillionth of a gram [3].
TB-500 and BPC-157 come from different proteins and both lack safety answers
TB-500 copies thymosin beta-4's actin-holding stretch; actin is needed when your cells move [1][5]. BPC-157 copies part of a different protein that comes from the stomach.
Both are unapproved; the 2026 Sports Medicine review considered muscle and joint injury claims but found scarce human safety evidence [15]. Their different origins don't establish safe treatment or useful recovery for you.
TB-500 human trial claims may refer to the longer protein instead
A finished human comparison trial hasn't established treatment effects for TB-500 [5]. For Phase 1, the early safety test, researchers used thymosin beta-4, tolerated up to 1260 milligrams [6].
The cited review mentions dry-eye trials of thymosin beta-4 without giving their findings [5]. You can't treat missing findings as proof of useful human healing.
TB-500 withdrawal means an ended pharmacy request rather than drug approval
TB-500 remains unapproved for treating illness, though suppliers sell research supplies [16]. FDA's ingredient name means the copied thymosin beta-4 piece, rather than the longer protein.
FDA put TB-500 in Category 2, its serious-risk group, in 2023 [16]. The request to permit TB-500 pharmacy use later appeared as withdrawn, meaning someone ended the request.
The pharmacy-use explanation describes why ending that request didn't approve treatment. Your prescription doesn't provide drug approval or establish permission to prepare the ingredient.
TB-500 sports rules cover time away from competition too
The World Anti-Doping Agency, or WADA, prohibits TB-500 and thymosin beta-4 for covered athletes [15]. The ban applies during competitions and throughout the time between contests.
Tests in people and horses can find traces of prohibited use. Your health question is separate from an athlete's right to compete.
TB-500 racehorse use raised concern about cheating rather than proving healing
TB-500 appeared in horse sport through animal products and medicines made to order. That use led researchers to devise blood and urine tests detecting tiny traces.
Use in horses raised sports-rule concerns, without establishing an approved treatment [15]. Detecting the copied substance doesn't establish useful healing for you or other patients.
TB-500 legality depends on where you live and how medicine is prepared
On FDA's page dated April 22, 2026, you can find the TB-500 pharmacy request as withdrawn [16][17]. TB-500 sits outside Category 2, FDA's serious-risk group for pharmacy ingredients.
Ending the request didn't approve treatment or establish permission for patient-specific pharmacy medicine. FDA hasn't stated what the ended request permits a pharmacy to do, and local prescription and sports rules also matter.
Your personal access question also depends on your local law. The legal explanation gives general facts rather than personal legal advice.
A TB-500 prescription still leaves the pharmacy’s ingredient checks unresolved
FDA gives no clear answer for routinely preparing TB-500 medicine for named patients. The request ended outside Category 2, the serious-risk group, while the safety concerns remain [16][17].
The ended request's effect on pharmacy permission remains unexplained by FDA [17]. Your doctor can assess your health, but the pharmacy must also meet ingredient rules.
A prescription doesn't supply a missing legal basis for preparing the copied part. Your access question needs an answer about pharmacy permission as well as medical care.
FDA’s TB-500 advice meeting has not supplied a published vote
FDA flagged thymosin beta-4 fragment, also called TB-500, for possible serious pharmacy-use risks [16]. The September 29, 2023 update put the ingredient in Category 2, the serious-risk group.
On the FDA page dated April 22, 2026, the entry shows the request ended, outside Category 2. TB-500 appeared on the July 23-24, 2026 agenda for possible use in medicine prepared separately for each patient.
Staff at FDA advised against including the ingredient; no vote was published by September 2026 [18]. Your pharmacy needs a permission decision, which an announced discussion doesn't supply.